Enspire DBS Therapy Raises $10.3M in Series B1 Funding

Why It Matters

The infusion of capital accelerates a pivotal trial that could deliver the first FDA‑cleared neuromodulation therapy for post‑stroke rehabilitation, reshaping the neuro‑rehab market.

Key Takeaways

• $10.3M Series B1 round led by Genesys Capital.
• Funds target enrollment in RESTORE DBS+Rehab trial.
• Board adds Genesys Capital partner Jamie Stiff.
• Cleveland Clinic remains strategic investor.
• Therapy aims to restore upper‑extremity function after stroke.

Pulse Analysis

Stroke remains a leading cause of long‑term disability, with millions of survivors experiencing persistent arm weakness that limits daily activities. Traditional physical therapy often yields modest gains, prompting researchers to explore neuromodulation techniques that can directly rewire damaged neural circuits. Deep‑brain stimulation, long used for movement disorders, is now being paired with intensive rehabilitation to amplify neuroplasticity, offering a promising avenue to address the unmet need for functional recovery in chronic stroke patients.

Enspire DBS Therapy’s RESTORE trial represents a critical test of this DBS + Rehab concept. The multicenter, randomized study enrolls patients with chronic upper‑extremity impairment, delivering targeted stimulation to motor pathways while participants engage in structured rehabilitation protocols. Early feasibility data suggest synergistic effects, with improved motor scores beyond rehabilitation alone. Success in RESTORE would not only validate the therapeutic hypothesis but also position Enspire as a first‑to‑market player, potentially securing premium reimbursement and establishing a new standard of care for post‑stroke neuro‑rehabilitation.

The recent $10.3 million Series B1 injection underscores growing investor confidence in neuro‑tech solutions. Genesys Capital’s lead role and board appointment signal strategic intent to scale clinical operations and prepare for regulatory submissions. Combined with continued backing from Cleveland Clinic and JobsOhio Ventures, the funding equips Enspire to expand trial sites, accelerate data collection, and strengthen its intellectual property portfolio. As the market for advanced stroke therapies expands, Enspire’s progress could catalyze further capital inflows and stimulate competition, ultimately accelerating innovation across the broader neuromodulation landscape.